Literature DB >> 9290955

Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation.

N Satake1, Y Ishida, Y Otoh, S Hinohara, H Kobayashi, A Sakashita, N Maseki, Y Kaneko.   

Abstract

CBP, which is located on 16p13 and encodes a transcriptional adaptor/coactivator protein, has been shown to fuse by the t(8;16)(p11;p13) translocation to MOZ on 8p11 in acute myeloid leukemia. We found a t(11;16)(q23;p13) in a child with therapy-related chronic myelomonocytic leukemia. Subsequent reverse transcriptase-polymerase chain reaction and direct sequencing analyses revealed the MLL-CBP fusion transcript in CMML cells. Because 11q23 translocations involving MLL and t(8;16) involving MOZ and CBP have been reported in therapy-related leukemias, both the MLL and CBP genes may be targets for topoisomerase II inhibitors. Accordingly, we believe that most t(11;16)-associated leukemias may develop in patients who have been treated with cytotoxic chemotherapy for primary malignant diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290955

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.

Authors:  I Kitabayashi; Y Aikawa; L A Nguyen; A Yokoyama; M Ohki
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  CBP/p300 interact with and function as transcriptional coactivators of BRCA1.

Authors:  G M Pao; R Janknecht; H Ruffner; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

Review 4.  A focused review of hematopoietic neoplasms occurring in the therapy-related setting.

Authors:  Liping Zhang; Sa A Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.

Authors:  I Kitabayashi; A Yokoyama; K Shimizu; M Ohki
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

6.  MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).

Authors:  O M Sobulo; J Borrow; R Tomek; S Reshmi; A Harden; B Schlegelberger; D Housman; N A Doggett; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 7.  Deregulated transcription factors in leukemia.

Authors:  Yutaka Shima; Issay Kitabayashi
Journal:  Int J Hematol       Date:  2011-08-09       Impact factor: 2.490

8.  Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.

Authors:  C Lavau; C Du; M Thirman; N Zeleznik-Le
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 9.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

10.  CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis.

Authors:  Salemiz Sandoval; Martina Pigazzi; Kathleen M Sakamoto
Journal:  Adv Hematol       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.